Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis

The Journal of Allergy and Clinical Immunology In Practice ◽

10.1016/j.jaip.2021.11.034 ◽

2022 ◽

Author(s):

Jonathan I. Silverberg ◽

Norma P.M. Rubini ◽

Mario C. Pires ◽

Ana B. Rossi ◽

Annie Zhang ◽

...

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis

Download Full-text

Immunodeficiencies in severe atopic dermatitis. Depressed chemotaxis and lymphocyte transformation

Archives of Dermatology ◽

10.1001/archderm.112.10.1391 ◽

1976 ◽

Vol 112 (10) ◽

pp. 1391-1396 ◽

Author(s):

J. L. Rogge

Keyword(s):

Atopic Dermatitis ◽

Lymphocyte Transformation ◽

Severe Atopic Dermatitis

Download Full-text

Elevated RANTES Levels in Plasma or Skin and Decreased Plasma IL-10 Levels in Subsets of Patients With Severe Atopic Dermatitis

Archives of Dermatology ◽

10.1001/archderm.136.1.125 ◽

2000 ◽

Vol 136 (1) ◽

pp. 125-126 ◽

Author(s):

Y. Niwa

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis

Download Full-text

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct03989349 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis

Download Full-text

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct04162769 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Safety And Efficacy

Download Full-text

Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct04178967 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety

Download Full-text

Faculty Opinions recommendation of Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718101782.793483405 ◽

2013 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Atopic Dermatitis ◽

Combined Therapy ◽

Severe Atopic Dermatitis ◽

Download Full-text

Faculty Opinions recommendation of Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718485867.793499544 ◽

2014 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis

Download Full-text

Faculty Opinions recommendation of Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725267890.793505964 ◽

2015 ◽

Author(s):

Ramsay Fuleihan ◽

Whitney Stevens

Keyword(s):

Atopic Dermatitis ◽

Molecular Signature ◽

Severe Atopic Dermatitis

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793555539 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793545728 ◽

2018 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Download Full-text